Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: A proof of concept

Translational Psychiatry

Volumn 1, Issue , 2011, Pages

  Kaddurah Daouk, R ^a   Boyle, S H ^a   Matson, W ^b   Sharma, S ^b   Matson, S ^b,c   Zhu, H ^d   Bogdanov, M B ^e   Churchill, E ^a   Krishnan, R R ^a,f   Rush, A J ^f   Pickering, E ^g   Delnomdedieu, M ^g  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d NORTH CAROLINA STATE UNIVERSITY   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f DUKE NUS MEDICAL SCHOOL   (Singapore)

^g PFIZER INC   (United States)

Author keywords

Major depressive disorder; Metabolomics; Placebo; Sertraline

Indexed keywords

SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ARTICLE; BLOOD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR DEPRESSION; MALE; METABOLISM; METABOLOMICS; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; OUTPATIENT; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS;

ADULT; CHROMATOGRAPHY, LIQUID; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LEAST-SQUARES ANALYSIS; MALE; METABOLIC NETWORKS AND PATHWAYS; METABOLOMICS; MIDDLE AGED; OUTPATIENTS; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 79960775080     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2011.22     Document Type: Article

References (43)

1. Trivedi MH. Major depressive disorder: Remission of associated symptoms. J Clin Psychiatry 2006; 67(Suppl 6): 27-32. (Pubitemid 44078110)
2. Sullivan GM, Oquendo MA, Simpson N, Van Heertum RL, Mann JJ, Parsey RV. Brain serotonin 1A receptor binding in major depression is related to psychic and somatic anxiety. Biol Psychiatry 2005; 58: 947-954. (Pubitemid 41790704)
3. Insel TR, Wang PS. The STA.R.*D trial: Revealing the need for better treatments. Psychiatr Serv 2009; 60: 1466-1467.
4. Ressler KH, Nemeroff CB. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 2000; 12(Suppl 1): 2-19.
5. Malhi GS, Parker GB, Greenwood J. Structural and functional models of depression: From sub-types to substrates. Acta Psychiatr Scand 2005; 111: 94-105. (Pubitemid 40293176)
6. Leonard BE. Psychopathology of depression. Drugs Today 2007; 43: 705-716. (Pubitemid 350220794)
7. Katz MM, Bowden CL, Frazer A. Rethinking depression and the actions of antidepressants: Uncovering the links between the neural and behavioral elements. J Affect Disord 2010; 120: 16-23.
8. Nutt DJ. The role of dopamine and norepinephrine in depression and antidepressant treatment. J Clin Psychiatry 2006; 67(Suppl 6): 3-8. (Pubitemid 44078106)
9. Nutt DJ. Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry 2008; 69(Suppl E1): 4-7.
10. Charney DS. Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry 1998; 59(Suppl 14): 11-14. (Pubitemid 28462383)
11. Brunoni AR, Fraguas R, Fregni F. Pharmacological and combined interventions for the acute depressive episode: Focus on efficacy and tolerability. Ther Clin Risk Manag 2009; 5: 897-910.
12. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: Variable, substantial, and growing. JAMA 2002; 287: 1840-1847. (Pubitemid 34303629)
13. Kirsch I. Challenging received wisdom: Antidepressant and the placebo effect. Mcgill J Med 2008; 11: 219-222.
14. Kaddurah-Daouk R, Kristal BS, Weinshilboum RM. Metabolomics: A global biochemical approach to drug response and disease. Annu Rev Pharmicol Toxicol 2008; 48: 653-683. (Pubitemid 351738167)
15. Kadddurah-Daouk R, Krishnan KR. Metabolomics: A global biochemical approach to the study of central nervous system diseases. Neruopsychopharmacology 2009; 34: 173-186.
16. Kristal BS, Shurubor Yl, Kaddurah-Daouk R, Matson WR. Metabolomics in the study of aging and caloric restriction. Methods Mol Biol 2007; 371: 393-409. (Pubitemid 350183437)
17. Holmes E, Wilson ID, Nicholson JK. Metabolic phenotyping in health and disease. Cell 2008; 134: 714-717.
18. Han X, Yang J, Yang K, Zhao Z, Abendschein DR, Gross RW. Alterations in myocardial cardiolipin content and composition occur at the very earliest stages of diabetes: A shotgun lipidomics study. Biochemistry 2007; 46: 6417-6428. (Pubitemid 46842885)
19. Han X. Potential mechanisms contributing to the sulfatide depletion at the earliest clinically recognizable stage of Alzheimer's disease: A tale of shotgun lipidomics. J Neurochem 2007; 103: 171-179.
20. Paige LA, Mitchell MW, Krishnan KR, Kaddurah-Daouk R, Steffens DC. A preliminary metabolomics analysis of older adults with and without depression. Int J Geriatr Psychiatry 2007; 22: 418-423. (Pubitemid 46831684)
21. Steffens DC, Jiang W, Krishnan KR, Karoly ED, Mitchell MW, O'Connor CM et al. Metabolomic differences in heart failure patients with and without major depression. J Geriatr Psychiatry Neurol 2010; 23: 136-146.
22. Ji Y, Zhu H, Jenkins GD, Biernacka J, Snyder K, Drews M et al. Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: Pharmacometabolomics-informed pharmacogenomics. Clin Pharmacol Ther 2011; 89: 97-104.
23. Rozen S, Cudkowicz ME, Bogdanov M, Matson WR, Kristal BS, Beecher C et al. Metabolomic analysis and signatures in motor neuron disease. Metabolomics 2005; 1: 101-108. (Pubitemid 40778831)
24. Bogdanov M, Matson WR, Wang L, Matson T, Saunders-Pullman R, Bressman SS et al. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 2008; 131(Part 2): 389-396. (Pubitemid 351197614)
25. Patkar AA, Rozen S, Mannelli P Matson W, Pae CU, Krishnan KR, Kaddurah-Daouk R. Alterations in tryptophan and purine metabolism in cocaine addiction: A metabolomics study. Psychopharmacology (Berl) 2009; 206: 479-489.
26. Mannelli P, Patkar A, Rozen S, Matson W, Krishnan R, Kaddurah-Daouk R. Opioid use affects antioxidant activity and purine metabolism: Preliminary results. Hum Psychopharmacol 2009; 24: 479-489.
27. Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM et al. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry 2007; 12: 934-935.
28. Yao JK, Dougherty Jr. GG, Reddy RD, Keshavan MS, Montrose DM, Matson WR et al. Altered interactions of tryptophan metabolites in first-episode neuroleptic-naïve patients with schizophrenia. Mol Psychiatry 2009; 15: 938-953.
29. Yao JK, Dougherty Jr. GG, Reddy RD, Keshavan MS, Montrose DM, Matson WR et al. Homeostatic imbalance of purine catabolism in first-episode neutroleptic-naïve patients with schizophrenia. PLoS One 2010; 5: E9508.
30. Hamilton M. A Rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-61.
31. Beal MF, Swartz KJ, Isacson O. Developmental changes in brain kynurenic acid concentrations. Brain Res Dev Brain Res 1992; 68: 136-139.
32. Shi H, Vigneau-Callahan KE, Shestopalov AI, Milbury PE, Matson WR, Kristal BS. Characterization of diet-dependent metabolic serotypes: Proof of principle in female and male rats. J. Nutr 2002; 132: 1031-1038. (Pubitemid 34493570)
33. Paolucci U, Vigneau-Callahan KE, Shi H, Matson WR, Kristal BS. Development of biomarkers based on diet-dependent metabolic serotypes: Characteristics of componentbased models of metabolic serotypes. OMICS 2004; 8: 221-238. (Pubitemid 39425673)
34. Paolucci U, Vigneau-Callahan KE, Shi H, Matson WR, Kristal BS. Development of biomarkers based on diet-dependent metabolic serotypes: Concerns and approaches for cohort and gender issues in serum metabolome studies. OMICS 2004; 8: 209-220. (Pubitemid 39425672)
35. Shi H, Paolucci U, Vigneau-Callahan KE, Milbury PE, Matson WR, Kristal BS. Development of biomarkers based on diet-dependent metabolic serotypes: Practical issues in development of expert system-based classification models in metabolomic studies. OMICS 2004; 8: 197-208. (Pubitemid 39425671)
36. Volicer L, Langlais PJ, Matson WR, Mark KA, Gamache PH. Serotoninergic system in dementia of the Alzheimer type. Abnormal forms of 5-hydroxytryptophan and serotonin in cerebrospinal fluid. Arch Neurol 1985; 42: 1158-1161. (Pubitemid 16214089)
37. Godefroy F, Matson WR, Gamache PH, Weil-Fugazza J. Simultaneous measurements of tryptophan and its metabolites, kynurenine and serotonin, in the superficial layers of the spinal dorsal horn. A study in normaland arthritic rats. Brain Res 1990; 526: 169-172. (Pubitemid 20273580)
38. Beal MF, Matson WR, Swartz KJ, Gamache PH, Bird ED. Kynurenine pathway measurements in Huntington0s disease striatum: Evidence for reduced formation of kynurenic acid. J Neurochem 1990; 55: 1327-1339.
39. Loeffler DA, LeWitt PA, Juneau PL, Camp DM, DeMaggio AJ, Havaich MK et al. Influence of repeated levodopa administration on rabbit striatal serotonin metabolism, and comparison between striatal and CSF alterations. Neurochem Res 1998; 23: 1521-1525. (Pubitemid 28516291)
40. Erikson L, Johaannson E, Kettanah-Wold N, Wold S. Multi- and megavariate data analysis. Umetyrics AB, Malmo: Sweden, 2001.
41. Wurtman RJ, Axelrod J. The pineal gland. Sci Am 1965; 213: 50-60.
42. Mullen PE, Leone RM, Hooper J, Smith I, Silman RE, Finnie M et al. Pineal 5-methoxy tryptophol in man. Psychoneuroendocrinology 1979; 2: 117-126. (Pubitemid 10235530)
43. Reiter RJ. The pineal gland: An intermediary between the environment and the endocrine system. Psychoneuroendocrinology 1983; 8: 31-40. (Pubitemid 13064648)